GB201122430D0 - Reconstitution method for high concentration dry protein formulation - Google Patents

Reconstitution method for high concentration dry protein formulation

Info

Publication number
GB201122430D0
GB201122430D0 GBGB1122430.0A GB201122430A GB201122430D0 GB 201122430 D0 GB201122430 D0 GB 201122430D0 GB 201122430 A GB201122430 A GB 201122430A GB 201122430 D0 GB201122430 D0 GB 201122430D0
Authority
GB
United Kingdom
Prior art keywords
high concentration
dry protein
protein formulation
reconstitution method
concentration dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1122430.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XSTALBIO Ltd
Original Assignee
XSTALBIO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XSTALBIO Ltd filed Critical XSTALBIO Ltd
Priority to GBGB1122430.0A priority Critical patent/GB201122430D0/en
Publication of GB201122430D0 publication Critical patent/GB201122430D0/en
Priority to JP2014548210A priority patent/JP2015511129A/ja
Priority to PCT/GB2012/053266 priority patent/WO2013093525A1/en
Priority to IN1381MUN2014 priority patent/IN2014MN01381A/en
Priority to BR112014015605A priority patent/BR112014015605A2/pt
Priority to US14/367,715 priority patent/US20140308293A1/en
Priority to EP12813947.4A priority patent/EP2793852A1/en
Priority to CA2859287A priority patent/CA2859287A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
GBGB1122430.0A 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation Ceased GB201122430D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1122430.0A GB201122430D0 (en) 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation
JP2014548210A JP2015511129A (ja) 2011-12-23 2012-12-24 高濃度乾燥タンパク質製剤のための再構成方法
PCT/GB2012/053266 WO2013093525A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations
IN1381MUN2014 IN2014MN01381A (enExample) 2011-12-23 2012-12-24
BR112014015605A BR112014015605A2 (pt) 2011-12-23 2012-12-24 método de reconstituição para formulações de proteína seca de alta concentração
US14/367,715 US20140308293A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations
EP12813947.4A EP2793852A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations
CA2859287A CA2859287A1 (en) 2011-12-23 2012-12-24 Reconstitution method for high concentration dry protein formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1122430.0A GB201122430D0 (en) 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation

Publications (1)

Publication Number Publication Date
GB201122430D0 true GB201122430D0 (en) 2012-02-08

Family

ID=45695059

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1122430.0A Ceased GB201122430D0 (en) 2011-12-23 2011-12-23 Reconstitution method for high concentration dry protein formulation

Country Status (8)

Country Link
US (1) US20140308293A1 (enExample)
EP (1) EP2793852A1 (enExample)
JP (1) JP2015511129A (enExample)
BR (1) BR112014015605A2 (enExample)
CA (1) CA2859287A1 (enExample)
GB (1) GB201122430D0 (enExample)
IN (1) IN2014MN01381A (enExample)
WO (1) WO2013093525A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201313368D0 (en) 2013-07-26 2013-09-11 Xstalbio Ltd Novel Reconstitution devices
US20170274012A1 (en) * 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
US10143625B2 (en) * 2015-03-17 2018-12-04 Recon Therapeutics, Inc. Pharmaceutical reconstitution
JP7114567B2 (ja) 2016-08-17 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 生体分子を含む高濃縮液体製剤の調製のためのプロセス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178884A (en) * 1988-05-18 1993-01-12 Cryopharm Corporation Lyophilized and reconstituted red blood cell compositions
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations

Also Published As

Publication number Publication date
IN2014MN01381A (enExample) 2015-04-17
JP2015511129A (ja) 2015-04-16
EP2793852A1 (en) 2014-10-29
US20140308293A1 (en) 2014-10-16
BR112014015605A2 (pt) 2017-07-04
WO2013093525A1 (en) 2013-06-27
CA2859287A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
TN2014000431A1 (en) Antibody formulatoin
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
IL222120A (en) Annals (indole-1-yl) -carbonylalkyl, process for preparation, pharmaceutical preparations containing them and their use in the preparation of cancer drugs
LT2807159T (lt) Nauji indolizino junginiai, jų gamybos būdai ir juos turinčios farmacinės kompozicijos, skirtos vėžio gydymui
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
EA033444B1 (ru) Снижение вязкости фармацевтических составов
PH12015502535A1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
PH12014501991B1 (en) Phenicol antibacterials
IL240496B (en) History of pyridine, process for their preparation, pharmaceutical preparations containing them and their use in medicine
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
NZ702288A (en) Stabilized formulations containing anti-dll4 antibodies
PL2911524T5 (pl) Sposób wytwarzania kompozycji białkowych o słabej rozpuszczalności, otrzymane kompozycje i ich zastosowanie w produktach wypieku pieczywa
GB201122430D0 (en) Reconstitution method for high concentration dry protein formulation
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
WO2011133894A3 (en) Protein drug formulations and packages
MX2015013160A (es) Metodo y productos para mejorar la absorcion celular de farmaco y suplementos dieteticos.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)